David M. Rubenstein - Aug 5, 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, As Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Aug 5, 2024
Transactions value $
$0
Form type
4
Date filed
8/7/2024, 04:06 PM
Previous filing
Jun 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +5.05K $0.00 5.05K Aug 5, 2024 Common Stock 5.05K $83.75 Direct F1
transaction MRNA Stock Option (Right to Buy) Award $0 +4.07K $0.00 4.07K Aug 5, 2024 Common Stock 4.07K $83.75 Direct F2
transaction MRNA Restricted Stock Units Award $0 +850 $0.00 850 Aug 5, 2024 Common Stock 850 Direct F3, F4
transaction MRNA Restricted Stock Units Award $0 +677 $0.00 677 Aug 5, 2024 Common Stock 677 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will become fully vested and exercisable on August 5, 2025.
F2 This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F3 Restricted stock units convert into common stock on a one-for-one basis.
F4 The shares subject to this restricted stock unit award will vest in full on August 5, 2025.
F5 The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.